Warfarin compared with aspirin for older Chinese patients with stable coronary heart diseases and atrial fibrillation complications

International Journal of Clinical Pharmacology and Therapeutics

Volumn 52, Issue 6, 2014, Pages 454-459

  Liu, Xinbing ^a   Huang, Hongman ^a   Yu, Jianhua ^a   Cao, Guoliang ^b   Feng, Liuliu ^a   Xu, Qitan ^a   Zhang, Shufu ^a   Zhou, Mingcheng ^c   Li, Yigang ^d  

^a Shanghai Shidong Hospital   (China)

^b No 3 People's Hospital   (China)

^c Department of Cardiology An Tu Hospital   (China)

^d XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Anticoagulation therapy; Atrial fibrillation; Older patient; Stable coronary heart disease

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

AGED; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CAUSE OF DEATH; CHINESE; CHRONIC BRONCHITIS; CONTROLLED STUDY; DIGESTIVE SYSTEM HEMORRHAGE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EMBOLISM; FEMALE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SUBARACHNOID HEMORRHAGE; TREATMENT DURATION;

AGE FACTORS; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; BLOOD COAGULATION; CHINA; CORONARY DISEASE; FEMALE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; PROSPECTIVE STUDIES; STROKE; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 84902138748     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201996     Document Type: Article

References (18)

1. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip GY, Witteman JC. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006; 27: 949-953. CrossRef PubMed
2. Fiore LD. Anticoagulation: risks and benefits in atrial fibrillation. Geriatrics. 1996; 51: 22-24, 27-28, 31. PubMed
3. Kralev S, Schneider K, Lang S, Süselbeck T, Borggrefe M. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS ONE. 2011; 6: e24964. CrossRef PubMed
4. Lechat P, Lardoux H, Mallet A, Sanchez P, Derumeaux G, Lecompte T, Maillard L, Mas JL, Mentre F, Pousset F, Lacomblez L, Pisica G, Solbes-Latourette S, Raynaud P, Chaumet-Riffaud P; FFAACS (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané) Investigators. Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané; FFAACS). Cerebrovasc Dis. 2001; 12: 245-252. CrossRef PubMed (Pubitemid 32973957)
5. Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL; SPORTIF Investigators. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J. 2006; 152: 967-973. CrossRef PubMed (Pubitemid 44637136)
6. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GY. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141: e531S-575S.
7. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med. 2001; 40: 1183-1188. CrossRef PubMed (Pubitemid 34110494)
8. Chinese Society of Cardiology. [Guideline for diagnosis and treatment of patients with chronic stable angina (no abstract)]. Zhonghua Xin Xue Guan Bing Za Zhi. 2007; 35: 195-206. PubMed
9. Johnson CE, Lim WK, Workman BS. People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up. J Am Geriatr Soc. 2005; 53: 655-659. CrossRef PubMed (Pubitemid 41623489)
10. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HASBLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138: 1093-1100. CrossRef PubMed
11. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray EBAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007; 370: 493-503. CrossRef PubMed (Pubitemid 47212371)
12. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the ACC/AHA Task Force on Practice Guidelines and the ESC Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006; 114: e257-e354. PubMed
13. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA III, Page RL, Ezekowitz MD, Slotwiner DJ, Jackman WM, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Le Heuzey JY, Crijns HJ, Lowe JE, Curtis AB, Olsson S, et al; ACCF/AHA Task Force Members. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 123: 104-123. CrossRef PubMed
14. Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, Xavier D, Kim SS, Omar R, Dans AL, Tan RS, Chen JH, Tanomsup S, Watanabe M, Koyanagi M, Ezekowitz MD, Reilly PA, Wallentin L, Yusuf S; RE-LY Investigators. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke. 2013; 44: 1891-1896. CrossRef PubMed
15. Shen AY, Chen W, Yao JF, Brar SS, Wang X, Go AS. Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation. CNS Drugs. 2008; 22: 815-825. CrossRef PubMed
16. Suzuki S, Yamashita T, Kato T, Fujino T, Sagara K, Sawada H, Aizawa T, Fu LT. Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation. Circ J. 2007; 71: 761-765. CrossRef PubMed (Pubitemid 46683370)
17. Kim JH, Song YB, Shin DH, Kim JS, Choi JO, On YK, Kim JS. How well does the target INR level maintain in warfarin-treated patients with non-valvular atrial fibrillation? Yonsei Med J. 2009; 50: 83-88. CrossRef PubMed
18. Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, Raunsø J, Tolstrup JS, Hansen PR, Gislason GH, Torp-Pedersen C. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost. 2011; 106: 739-749. CrossRef PubMed